查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1476379

到 2030 年糖尿病神经病变治疗市场预测：按类型、治疗、药物类别、分销管道、最终用户和地区进行的全球分析

Diabetic Neuropathy Treatment Market Forecasts to 2030 - Global Analysis By Type (Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy, Peripheral Neuropathy and Other Types), Treatment, Drug Class, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球糖尿病神经病变治疗市场规模为 46 亿美元，预计预测期内复合年增长率为 7.5%，到 2030 年将达到 76 亿美元。

糖尿病神经病变治疗是一系列医疗干预措施和生活方式改变，旨在控製糖尿病引起的神经病变病变的症状和併发症。糖尿病神经病变是一种由于与糖尿病相关的长期高血糖状况神经病变。治疗方法通常包括药物、生活方式改变以及有时替代疗法的组合，以缓解疼痛、改善神经功能并防止进一步的神经损伤。

根据美国疾病管制与预防中心 (CDC) 的美国糖尿病统计报告，2018 年有 3,420 万美国（占美国人口的 10.5%）被临床诊断患有糖尿病。

糖尿病盛行率上升

随着被诊断为糖尿病的人数不断增加，对有效神经病变治疗的需求也显着增加。这一趋势是由生活方式的改变、人口老化以及早期诊断意识的提高等因素所推动的。因此，製药公司和医疗保健提供者正在集中更多资源来开发和提供创新解决方案来解决糖尿病神经病变。因此，由于糖尿病盛行率的上升，市场正在经历显着的快速成长。

治疗效果有限

儘管治疗方法取得了进展，糖尿病神经病变的治疗方法仍面临挑战，有限的疗效仍然是一个重大问题。目前的治疗方法通常着重于控制症状，而不是解决根本原因。这项限制凸显了市场需要持续研究和创新，以针对糖尿病患者神经病变的潜在机制制定更有效的策略。

治疗进展

神经减压手术、利用干细胞的再生医学和标靶药物传输系统等创新治疗方法正不断出现。此外，神经刺激和透过穿戴式技术进行连续监测等非侵入性技术也显示出前景。根据个别基因特征客製化治疗方案的精准医学也是一个新领域。这些进展代表了糖尿病神经病变管理方法转向更有效、个人化和整体性方法的转变。

昂贵的治疗费用

治疗费用往往难以承担，限制了获得基本治疗方法的机会，并加剧了已经在应对糖尿病相关神经病变挑战的个人的负担。这种经济负担旨在使这些治疗方法更容易获得和负担得起，以确保糖尿病神经病变患者得到全面护理，这凸显了干预措施的迫切需求。结果，市场受到高昂费用的困扰，为寻求治疗的患者造成了障碍。

COVID-19 的影响：

COVID-19 的爆发对糖尿病神经病变治疗市场产生了重大影响。由于医疗资源的重新分配而导致诊断和治疗的延误，导致患者病情恶化。虽然远端医疗在咨询方面受到重视，但药品供应链的中断影响了药品的取得。临床试验和研究也面临挫折，减缓了新治疗方法的发展。

局部神经病变预计将成为预测期内最大的部分

局部神经病变部分预计将成为预测期内最大的部分。目前的治疗方法包括止痛药物、物理治疗和改变生活方式以控制血糖值。神经刺激技术和再生医学等新治疗方法有望解决潜在的神经损伤。然而，针对每位患者的需求量身定制的个人化方法仍然是优化糖尿病神经病变管理挑战结果的重要研究领域。

预计诊所业在预测期内的复合年增长率最高。

预计诊所在预测期内将经历最高的复合年增长率。这些诊所提供各种服务，包括诊断测试、药物管理、物理治疗和生活方式咨询。这些诊所聘用熟练的医疗保健专业人员，例如神经科、内分泌科医生和物理治疗师，他们共同製定个人化的治疗计划。这些诊所旨在透过管理症状、预防併发症和促进整体健康来改善患者的生活品质。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。主要参与者专注于开发创新治疗方法满足未满足的患者需求。此外，有利的报销政策和医疗基础设施也有助于市场扩张。由于持续的研发活动，市场预计将持续成长，并有望为相关人员提供利润丰厚的机会。

复合年增长率最高的地区：

由于糖尿病盛行率上升等多种因素，预计亚太地区在预测期内将维持最高的复合年增长率。市场提供了多种糖尿病神经病变的治疗选择，包括药物、物理治疗、神经刺激技术和生活方式改变。製药公司正在积极开发新药和治疗方法来解决这个问题。医疗设备和诊断技术的进步也促进了市场的成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球糖尿病神经病变治疗市场：依类型

  • 自主神经病变
  • 近端神经病变
  • 局部神经病变
  • 週边神经病变
  • 其他类型

第六章全球糖尿病神经病变治疗市场：依治疗分类

  • 减缓疾病的进展
  • 缓解疼痛
  • 併发症的处理
  • 物理治疗
  • 药品
  • 其他治疗

第七章全球糖尿病神经病变治疗市场：依药物类别

  • 非类固醇消炎剂
  • 阿片类药物
  • 抗忧郁症
  • 抗癫痫药
  • 其他药物类别

第八章全球糖尿病神经病变治疗市场：依通路

  • 医院药房
  • 零售药房
  • 网路药房
  • 专科诊所

第九章全球糖尿病神经病变治疗市场：依最终用户分类

  • 医院
  • 诊所
  • 门诊手术中心
  • 居家照护环境
  • 其他最终用户

第十章全球糖尿病神经病变治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • GlaxoSmithKline Plc
  • Lupin Ltd
  • Depomed, Inc
  • Astellas Pharma Inc
  • Meda Pharma GmBH & Co. KG
  • Glenmark Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Asprius Lifesciences
  • Vertex Pharmaceuticals
Product Code: SMRC25925

According to Stratistics MRC, the Global Diabetic Neuropathy Treatment Market is accounted for $4.6 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 7.5% during the forecast period. Diabetic neuropathy treatment is the various medical interventions and lifestyle modifications aimed at managing the symptoms and complications of neuropathy caused by diabetes. It is a type of nerve damage that can result from prolonged high blood sugar levels associated with diabetes. The treatment approach typically involves a combination of medications, lifestyle changes, and sometimes alternative therapies to alleviate pain, improve nerve function, and prevent further nerve damage.

According to National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), it was found that 34.2 million U.S. individuals (10.5% of the U.S. population) were clinically diagnosed with diabetes in 2018.

Market Dynamics:

Driver:

Rising prevalence of diabetes

With more individuals being diagnosed with diabetes, the demand for effective neuropathy treatments has increased significantly. This trend is driven by factors such as lifestyle changes, aging populations, and heightened awareness leading to early diagnosis. As a result, pharmaceutical companies and healthcare providers are focusing more resources on developing and providing innovative solutions to address diabetic neuropathy. Thus, the market is experiencing a notable surge due to the rising prevalence of diabetes.

Restraint:

Limited efficacy of treatments

Despite advancements, treatments for diabetic neuropathy face challenges, with limited efficacy remaining a significant concern. Current therapies often focus on symptom management rather than addressing the underlying causes. This limitation underscores the need for continued research and innovation in the market to develop more effective strategies that target the root mechanisms of neuropathy in diabetic patients.

Opportunity:

Advancements in treatment

Innovative therapies like nerve decompression surgery, regenerative medicine using stem cells, and targeted drug delivery systems are emerging. Moreover, non-invasive techniques like neurostimulation and wearable tech for continuous monitoring show promise. Precision medicine tailoring treatments to individual genetic profiles is another frontier. These developments signify a shift towards more effective, personalized, and holistic approaches in managing diabetic neuropathy.

Threat:

High cost of treatments

With treatments often priced beyond affordability, access to essential therapies becomes restricted, exacerbating the burden on individuals already grappling with the challenges of managing diabetes-related neuropathy. This financial strain underscores the pressing need for interventions aimed at making these treatments more accessible and affordable to ensure comprehensive care for those affected by diabetic neuropathy. Therefore, the market is plagued by exorbitant costs, creating barriers for patients seeking care.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Diabetic Neuropathy Treatment market. Delays in diagnosis and treatment due to healthcare resource reallocation led to worsening patient conditions. Telemedicine gained prominence for consultations, while disruptions in the pharmaceutical supply chain affected medication availability. Clinical trials and research also faced setbacks, slowing down the development of new treatment options.

The focal neuropathy segment is expected to be the largest during the forecast period

The focal neuropathy segment is expected to be the largest during the forecast period. Current therapies include pain management medications, physical therapy, and lifestyle modifications to control blood sugar levels. Emerging treatments such as nerve stimulation techniques and regenerative medicine show promise in addressing underlying nerve damage. However, personalized approaches tailored to individual patient needs remain a key area of research to optimize outcomes in this challenging aspect of diabetic neuropathy management.

The clinics segment is expected to have the highest CAGR during the forecast period

The clinics segment is expected to have the highest CAGR during the forecast period. These clinics provide a range of services, including diagnostic testing, medication management, physical therapy, and lifestyle counseling. They employ skilled healthcare professionals such as neurologists, endocrinologists, and physical therapists who work collaboratively to develop personalized treatment plans. These clinics aim to improve patients' quality of life by managing symptoms, preventing complications, and promoting overall well-being.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Key players are focusing on developing innovative therapies to address the unmet needs of patients. Additionally, favorable reimbursement policies and healthcare infrastructure are contributing to market expansion. With ongoing research and development activities, the market is poised for continued growth and is expected to offer lucrative opportunities for stakeholders.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors such as the increasing prevalence of diabetes. The market offers a range of treatment options for diabetic neuropathy, including medications, physical therapy, nerve stimulation techniques, and lifestyle modifications. Pharmaceutical companies are actively developing new drugs and therapies to address this condition. Technological advancements in medical devices and diagnostics have also contributed to the growth of the market.

Key players in the market

Some of the key players in Diabetic Neuropathy Treatment market include GlaxoSmithKline Plc, Lupin Ltd, Depomed, Inc, Astellas Pharma Inc, Meda Pharma GmBH & Co. KG, Glenmark Pharmaceuticals Ltd., Eli Lilly and Company, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., Novo Nordisk A/S, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novartis AG, Asprius Lifesciences, and Vertex Pharmaceuticals.

Key Developments:

In December 2023, Vertex Pharmaceuticals received FDA approval for CRISPR-based gene editing therapy, a strategy focused on developing and promoting non-opioid pain relievers Based on Vertex's Phase 2 clinical trial results for VX-548, highlighting alternative pain management strategies in diabetic peripheral neuropathy Thiah of the safe and consistent with the search for more effective treatments.

In July 2023, Asprius Lifesciences recently started treating diabetic neuropathy, a disease that causes nerve damage in different parts of the body the company has filed patents for a patented drug combination (FDC), indicating potential for peripheral nerve block.

Types Covered:

  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
  • Peripheral Neuropathy
  • Other Types

Treatments Covered:

  • Slow Progression of Diseases
  • Pain Relieving
  • Managing Complications
  • Physiotherapy
  • Drugs
  • Other Treatments

Drug Classes Covered:

  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioid
  • Anti-Depressants
  • Anti-Seizure
  • Other Drug Classes

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Diabetic Neuropathy Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Autonomic Neuropathy
  • 5.3 Proximal Neuropathy
  • 5.4 Focal Neuropathy
  • 5.5 Peripheral Neuropathy
  • 5.6 Other Types

6 Global Diabetic Neuropathy Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Slow Progression of Diseases
  • 6.3 Pain Relieving
  • 6.4 Managing Complications
  • 6.5 Physiotherapy
  • 6.6 Drugs
  • 6.7 Other Treatments

7 Global Diabetic Neuropathy Treatment Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Non-Steroidal Anti-Inflammatory Drugs
  • 7.3 Opioid
  • 7.4 Anti-Depressants
  • 7.5 Anti-Seizure
  • 7.6 Other Drug Classes

8 Global Diabetic Neuropathy Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Clinics

9 Global Diabetic Neuropathy Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Homecare Settings
  • 9.6 Other End Users

10 Global Diabetic Neuropathy Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 GlaxoSmithKline Plc
  • 12.2 Lupin Ltd
  • 12.3 Depomed, Inc
  • 12.4 Astellas Pharma Inc
  • 12.5 Meda Pharma GmBH & Co. KG
  • 12.6 Glenmark Pharmaceuticals Ltd.
  • 12.7 Eli Lilly and Company
  • 12.8 Abbott Laboratories
  • 12.9 F. Hoffmann-La Roche Ltd
  • 12.10 Johnson & Johnson
  • 12.11 Pfizer Inc.
  • 12.12 Novo Nordisk A/S
  • 12.13 Merck & Co., Inc.
  • 12.14 Teva Pharmaceutical Industries Ltd.
  • 12.15 AbbVie Inc.
  • 12.16 Novartis AG
  • 12.17 Asprius Lifesciences
  • 12.18 Vertex Pharmaceuticals

List of Tables

  • Table 1 Global Diabetic Neuropathy Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Diabetic Neuropathy Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Diabetic Neuropathy Treatment Market Outlook, By Autonomic Neuropathy (2021-2030) ($MN)
  • Table 4 Global Diabetic Neuropathy Treatment Market Outlook, By Proximal Neuropathy (2021-2030) ($MN)
  • Table 5 Global Diabetic Neuropathy Treatment Market Outlook, By Focal Neuropathy (2021-2030) ($MN)
  • Table 6 Global Diabetic Neuropathy Treatment Market Outlook, By Peripheral Neuropathy (2021-2030) ($MN)
  • Table 7 Global Diabetic Neuropathy Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Diabetic Neuropathy Treatment Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 9 Global Diabetic Neuropathy Treatment Market Outlook, By Slow Progression of Diseases (2021-2030) ($MN)
  • Table 10 Global Diabetic Neuropathy Treatment Market Outlook, By Pain Relieving (2021-2030) ($MN)
  • Table 11 Global Diabetic Neuropathy Treatment Market Outlook, By Managing Complications (2021-2030) ($MN)
  • Table 12 Global Diabetic Neuropathy Treatment Market Outlook, By Physiotherapy (2021-2030) ($MN)
  • Table 13 Global Diabetic Neuropathy Treatment Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 14 Global Diabetic Neuropathy Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 15 Global Diabetic Neuropathy Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 16 Global Diabetic Neuropathy Treatment Market Outlook, By Non-Steroidal Anti-Inflammatory Drugs (2021-2030) ($MN)
  • Table 17 Global Diabetic Neuropathy Treatment Market Outlook, By Opioid (2021-2030) ($MN)
  • Table 18 Global Diabetic Neuropathy Treatment Market Outlook, By Anti-Depressants (2021-2030) ($MN)
  • Table 19 Global Diabetic Neuropathy Treatment Market Outlook, By Anti-Seizure (2021-2030) ($MN)
  • Table 20 Global Diabetic Neuropathy Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 21 Global Diabetic Neuropathy Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 22 Global Diabetic Neuropathy Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 23 Global Diabetic Neuropathy Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 24 Global Diabetic Neuropathy Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 25 Global Diabetic Neuropathy Treatment Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 26 Global Diabetic Neuropathy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Diabetic Neuropathy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Diabetic Neuropathy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 29 Global Diabetic Neuropathy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 30 Global Diabetic Neuropathy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 31 Global Diabetic Neuropathy Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.